Efficacy and safety of infliximab biosimilar Inflectra ® in severe sarcoidosis

Infliximab, a monoclonal antibody against tumor necrosis factor alpha (TNF- α) is effective third-line therapy in severe sarcoidosis. The originator product of Infliximab, Remicade®, is expensive, limiting universal access. Recently, a less expensive biosimilar of infliximab, Inflectra®, has become available, but the efficacy and tolerability has not been studied in sarc oidosis.

Source: Respiratory Medicine - February 19, 2018 Category: Respiratory Medicine Authors: Milou C. Schimmelpennink, Adriane D.M. Vorselaars, Frouke T. van Beek, Heleen A. Crommelin H, Vera H.M. Deneer, Ruth G.M. Keijsers, Marcel Veltkamp Source Type: research